Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | PDE2A | O00408 | 4/20 | 0.44 |
| ▸ | AR | P10275 | 5/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2515789 | 0.84 | PTGDR2 (0.43) | MRGPRX4PDE2AALDH1A1MEN1TSHR | |
| SCHEMBL952338 | 0.80 | AR (0.65) | MRGPRX4PDE2AAR | |
| SCHEMBL31568536 | 0.80 | PDE2A (0.44) | MRGPRX4PDE2AARACACBALDH1A1 | |
| SCHEMBL9996467 | 0.80 | PDE2A (0.44) | MRGPRX4PDE2AARACACBALDH1A1 | |
| SCHEMBL15541043 | 0.80 | PDE2A (0.44) | MRGPRX4PDE2AARACACBALDH1A1 | |
| SCHEMBL2703782 | 0.78 | CES2 (0.50) | ARDAO | |
| SCHEMBL2140819 | 0.78 | PDE2A (0.42) | PDE2AALDH1A1MEN1KMT2ADAO | |
| SCHEMBL3033286 | 0.78 | PDE2A (0.39) | PDE2AALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL27908554 | 0.76 | MEN1 (0.44) | ARALDH1A1MAPTMEN1TSHR | |
| SCHEMBL29648890 | 0.76 | PDE2A (0.41) | MRGPRX4PDE2AALDH1A1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48335-E1 | Polymyxin derivatives as antimicrobial compounds | MONASH UNIVERSITY (AU) | 2020-12-01 | — | — | US | claimed |
| CN-106414480-B | Polymyxin derivatives as antimicrobial compounds | 莫纳什大学 | 2020-08-04 | — | — | CN | claimed |
| US-20170137469-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | MONASH UNIVERSITY (AU) | 2017-05-18 | — | — | US | claimed |
| EP-3126376-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | Monash University (AU) | 2017-02-08 | — | — | EP | claimed |
| WO-2015149131-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | MONASH UNIVERSITY (AU) | 2015-10-08 | — | — | WO | claimed |
| US-RE48335-E1 | Polymyxin derivatives as antimicrobial compounds | MONASH UNIVERSITY (AU) | 2020-12-01 | — | — | US | disclosed |
| CN-106414480-B | Polymyxin derivatives as antimicrobial compounds | 莫纳什大学 | 2020-08-04 | — | — | CN | disclosed |
| US-20170137469-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | MONASH UNIVERSITY (AU) | 2017-05-18 | — | — | US | disclosed |
| EP-3126376-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | Monash University (AU) | 2017-02-08 | — | — | EP | disclosed |
| WO-2015149131-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | MONASH UNIVERSITY (AU) | 2015-10-08 | — | — | WO | disclosed |
| EP-1957073-B1 | MEDICINAL DRUG | OTSUKA PHARMA CO LTD (JP) | 2014-04-23 | — | — | EP | disclosed |
| EP-2612858-A1 | STAT3/5 activation inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-07-10 | — | — | EP | disclosed |
| CN-101321529-A | Diaryl aether derivant as antineoplastic agent | OTSUKA PHARMA CO LTD (JP) | 2008-12-10 | — | — | CN | disclosed |
| WO-2008044667-A1 | STAT3/5 ACTIVATION INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-04-17 | — | — | WO | disclosed |
| US-20070270422-A1 | Aromatic Compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| CN-1993339-A | Aromatic compound | OTSUKA PHARMA CO LTD (JP) | 2007-07-04 | — | — | CN | disclosed |
| EP-1773797-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006014012-A2 | AROMATIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-02-09 | — | — | WO | disclosed |
| US-4689068-A | HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1987-08-25 | — | — | US | disclosed |
| EP-0191394-A1 | Isothioureas, process for their preparation and their use to combat undesirable plant growth | BASF Aktiengesellschaft (DE) | 1986-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270422-A1 | Aromatic Compounds | COL1A1, COL2A1, COL14A1 | MRGPRX4 712/4885PDE2A 3009/4885AR 189/4885 |
| US-20170137469-A1 | POLYMYXIN DERIVATIVES AS ANTIMICROBIAL COMPOUNDS | VIP, PEPD, NRDC | MRGPRX4 841/4885PDE2A 4201/4885AR 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.